X-ray Structural and Biological Evaluation of a Series of Potent and Highly Selective Inhibitors of Human Coronavirus Papain-like Proteases

Structure-guided design was used to generate a series of noncovalent inhibitors with nanomolar potency against the papain-like protease (PLpro) from the SARS coronavirus (CoV). A number of inhibitors exhibit antiviral activity against SARS-CoV infected Vero E6 cells and broadened specificity toward the homologous PLP2 enzyme from the human coronavirus NL63. Selectivity and cytotoxicity studies established a more than 100-fold preference for the coronaviral enzyme over homologous human deubiquitinating enzymes (DUBs), and no significant cytotoxicity in Vero E6 and HEK293 cell lines is observed. X-ray structural analyses of inhibitor-bound crystal structures revealed subtle differences between binding modes of the initial benzodioxolane lead (15g) and the most potent analogues 3k and 3j, featuring a monofluoro substitution at para and meta positions of the benzyl ring, respectively. Finally, the less lipophilic bis(amide) 3e and methoxypyridine 5c exhibit significantly improved metabolic stability and are viable candidates for advancing to in vivo studies.

[1]  E. Freire,et al.  The binding of HIV-1 protease inhibitors to human serum proteins. , 2003, Biophysical chemistry.

[2]  E. Purisima,et al.  Deubiquitination, a New Function of the Severe Acute Respiratory Syndrome Coronavirus Papain-Like Protease? , 2005, Journal of Virology.

[3]  Katrina Sleeman,et al.  Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease. , 2009, Journal of medicinal chemistry.

[4]  Robert Ménard,et al.  Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus papain-like protease , 2007, Archives of Biochemistry and Biophysics.

[5]  R. Pebody,et al.  Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. , 2012, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[6]  R. Copeland Determination of serum protein binding affinity of inhibitors from analysis of concentration-response plots in biochemical activity assays. , 2000, Journal of pharmaceutical sciences.

[7]  T. Welte,et al.  [SARS--Severe Acute Respiratory syndrome]. , 2003, Pneumologie.

[8]  U. Emirates b Middle East respiratory syndrome coronavirus (MERS-CoV): update , 2014 .

[9]  Arun K. Ghosh,et al.  Synergistic Inhibitor Binding to the Papain‐Like Protease of Human SARS Coronavirus: Mechanistic and Inhibitor Design Implications , 2013, ChemMedChem.

[10]  M. Catchpole,et al.  Novel coronavirus associated with severe respiratory disease: case definition and public health measures. , 2012, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[11]  Raymond C Stevens,et al.  Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Wentao Fu,et al.  A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication , 2008, Proceedings of the National Academy of Sciences.

[13]  Zhongbin Chen,et al.  Regulation of IRF-3-dependent Innate Immunity by the Papain-like Protease Domain of the Severe Acute Respiratory Syndrome Coronavirus , 2007, Journal of Biological Chemistry.

[14]  B. Berkhout,et al.  Croup Is Associated with the Novel Coronavirus NL63 , 2005, PLoS medicine.

[15]  Kui Li,et al.  Coronavirus Papain-like Proteases Negatively Regulate Antiviral Innate Immune Response through Disruption of STING-Mediated Signaling , 2012, PloS one.

[16]  Debbie C. Mulhearn,et al.  Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation. , 2010, Journal of medicinal chemistry.

[17]  R. Pebody,et al.  The United Kingdom public health response to an imported laboratory confirmed case of a novel coronavirus in September 2012. , 2012, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[18]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[19]  John Bechill,et al.  Identification of Severe Acute Respiratory Syndrome Coronavirus Replicase Products and Characterization of Papain-Like Protease Activity , 2004, Journal of Virology.

[20]  W. E. Barnette The synthesis and biology of fluorinated prostacyclins. , 1984, CRC critical reviews in biochemistry.

[21]  R. Ménard,et al.  The Papain-Like Protease from the Severe Acute Respiratory Syndrome Coronavirus Is a Deubiquitinating Enzyme , 2005, Journal of Virology.

[22]  Alexander E. Gorbalenya,et al.  Genomic Characterization of a Newly Discovered Coronavirus Associated with Acute Respiratory Distress Syndrome in Humans , 2012, mBio.

[23]  E. Hodgson,et al.  Interaction of methylenedioxyphenyl (1,3-benzodioxole) compounds with enzymes and their effects on mammals. , 1974, Drug metabolism reviews (Softcover ed.).

[24]  Zhongbin Chen,et al.  The Papain-Like Protease of Severe Acute Respiratory Syndrome Coronavirus Has Deubiquitinating Activity , 2005, Journal of Virology.

[25]  R. Sorenson,et al.  Novel inhibitors of bacterial virulence: development of 5,6-dihydrobenzo[h]quinazolin-4(3H)-ones for the inhibition of group A streptococcal streptokinase expression. , 2013, Bioorganic & medicinal chemistry.

[26]  B. Rha Update: Severe Respiratory Illness Associated with a Novel Coronavirus — Worldwide, 2012–2013 , 2013, MMWR. Morbidity and mortality weekly report.

[27]  Alexei Vagin,et al.  Molecular replacement with MOLREP. , 2010, Acta crystallographica. Section D, Biological crystallography.

[28]  T. Tong,et al.  Drug targets in severe acute respiratory syndrome (SARS) virus and other coronavirus infections. , 2009, Infectious disorders drug targets.

[29]  Christian Drosten,et al.  Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group , 2013, Journal of Virology.

[30]  V. Mićović,et al.  The Reduction of Acid Amides with Lithium Aluminum Hydride , 1953 .

[31]  Martyn D Winn,et al.  Macromolecular TLS refinement in REFMAC at moderate resolutions. , 2003, Methods in enzymology.

[32]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[33]  Jincun Zhao,et al.  Human Coronavirus EMC Is Not the Same as Severe Acute Respiratory Syndrome Coronavirus , 2013, mBio.

[34]  C. F. Wilkinson,et al.  Mechanism of the metabolism of 1,3-benzodioxoles to carbon monoxide. , 1984, Biochemical pharmacology.

[35]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[36]  R. Geffers,et al.  Efficient Replication of the Novel Human Betacoronavirus EMC on Primary Human Epithelium Highlights Its Zoonotic Potential , 2013, mBio.

[37]  B. Cowling,et al.  Incubation period as part of the case definition of severe respiratory illness caused by a novel coronavirus. , 2012, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[38]  T. Peters,et al.  All About Albumin: Biochemistry, Genetics, and Medical Applications , 1995 .

[39]  F. Lichtenberger,et al.  Abbreviations Used , 1979, Confronting the Bomb.

[40]  U. Baumann,et al.  An efficient one-step site-directed and site-saturation mutagenesis protocol. , 2004, Nucleic acids research.